OncoMatch/Clinical Trials/NCT06224049
Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T
Is NCT06224049 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies multiple treatments including hNeo-T and Cyclophosphamide for t-cell lymphoma.
Treatment: hNeo-T · Cyclophosphamide · Fludarabine — Objective: To evaluate the safety and tolerability of hNeo-T injection in patients with relapsed or refractory EBV-positive T-cell lymphoma. Secondary objective: To evaluate the effectiveness of hNeo-T injection, and to evaluate the objective response rate (ORR) and disease control rate (DCR) by Lugano2014 criteria; Progression-free survival (PFS), duration of response (DOR), and overall survival (OS ) followed. Objective of the exploratory study: To investigate the in vivo process of hNeo-T injection and describe the activity and related biological functions of hNeo-T cells in vivo, including but not limited to.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic therapy — first-line or above
Disease progression after adequate first-line systemic treatment, or disease progression ≥2 cycles (PD) after first-line or above systemic systemic treatment, or ≥4 cycles without remission (CR or PR)
Lab requirements
Blood counts
ANC ≥1×10^9/L, PLT ≥75×10^9/L, HGB ≥80g/L
Kidney function
serum creatinine ≤1.5x ULN
Liver function
ALT and AST ≤3x ULN (≤5x ULN in liver metastasis subjects); total bilirubin ≤1.5x ULN, or <3x ULN for Gilbert's Syndrome
Cardiac function
LVEF ≥50%
Laboratory test results and vital organ functions meet the following requirements: ... see full criteria for details
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06224049 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages